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Introduction
!
Pain secondary to chronic pancreatitis (CP) is
common and difficult tomanage. Although opioid
analgesics are commonly used, their adverse ef-
fects, including sedation, chronic constipation,
delirium, nausea, vomiting, narcotic bowel syn-
drome, respiratory depression, myoclonus, urin-
ary retention, and dependence, negatively impact
quality of life [1,2]. Endoscopic ultrasound–guid-
ed celiac plexus block (EUS-CPB) is a treatment
option for patients with CP that avoids these ad-
verse events. Approximately 60% of patients with
CP report relief of pain after EUS-CPB, with a
mean duration of 51 days [3]. Because the effect
of EUS-CPB is temporary, serial procedures are of-
ten required.
At our institution, the rate of major adverse
events is less than 1% [3,4]. Minor adverse events
may include transient diarrhea (4%–15%) and
postural hypotension (1%) of up to 48 hours’
duration [5,6]. The number of endoscopic ultra-
sound–guided celiac plexus block/neurolysis
(EUS-CPB/N) procedures that a single patient can
safely undergo has not been reported. Our objec-
tive was to report our experience of the safety
and efficacy of repeated EUS-CPB/N procedures
in a large cohort of patients.
Patients/Materials and methods
!
Study design
The study was conducted at the Indiana Universi-
ty Medical Center, Indianapolis, Indiana, USA. We
are a high-volume EUS center staffed by six ex-
perienced endosonographers and perform ap-
proximately 3000 procedures a year. Our prospec-
tively maintained EUS database was searched for
patients who had undergone EUS-CPB over a 17-
year period (1996–2012). Each medical record
was reviewed for the number of EUS-CPB proce-
dures, duration of pain relief, and adverse events.
Pain relief was defined as patient self-report of a
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Background and study aims: Endoscopic ultra-
sound–guided celiac plexus block (EUS-CPB) is
an established treatment for pain in patients
with chronic pancreatitis (CP), but the effective-
ness and safety of repeated procedures are un-
known. Our objective is to report our experience
of repeated EUS-CPB procedures within a single
patient.
Patients and methods: A prospectively main-
tained EUS database was retrospectively analyzed
to identify patients who had undergone more
than one EUS-CPB procedure over a 17-year peri-
od. The main outcome measures included num-
ber of EUS-CPB procedures for each patient, self-
reported pain relief, duration of pain relief, and
procedure-related adverse events.
Results: A total of 248 patients underwent more
than one EUS-CPB procedure and were included
in our study. Patients with known or suspected
CP (N=248) underwent a mean (SD) of 3.1 (1.6)
EUS-CPB procedures. In 76% of the patients with
CP, the median (range) duration of the response
to the first EUS-CPB procedure was 10 (1–54)
weeks. Lack of pain relief after the initial EUS-
CPB was associated with failure of the next EUS-
CPB (OR 0.17, 95%CI 0.06–0.54). Older age at first
EUS-CPB and pain relief after the first EUS-CPB
were significantly associated with pain relief after
subsequent blocks (P=0.026 and P=0.002, respec-
tively). Adverse events included peri-procedural
hypoxia (n=2) and hypotension (n=1) and post-
procedural orthostasis (n=2) and diarrhea (n=4).
No major adverse events occurred.
Conclusions: Repeated EUS-CPB procedures in a
single patient appear to be safe. Response to the
first EUS-CPB is associated with response to sub-
sequent blocks.
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reduction or elimination of pain after the procedure and was
treated as a binary variable (yes/no). No further attempt was
made to standardize the definition because of the retrospective
design of the study. The duration of pain relief was determined
by patient report rather than by the interval between proce-
dures. Adverse events were assessed by a telephone call 24 to 48
hours after the procedure, a review of the medical record for
emergency department visits or hospital admissions, and patient
questioning at the time of the subsequent EUS-CPB. In addition,
the following information was abstracted from each medical re-
cord: age, gender, indication, and number of EUS criteria for CP.
Institutional review board approval was obtained before initia-
tion of the study.
EUS-CPB procedure.
The EUS-CPB procedure was performed by one of six expert en-
dosonographers according to the standards outlined by the
American Society of Gastrointestinal Endoscopy [7]. A radial
and/or curvilinear echoendoscope (GF-UM20, GF-UM130, GF-
UM160, GF-UC140P-AL5; Olympus America, Center Valley, Penn-
sylvania, USA) was used to evaluate the pancreas for sonographic
criteria for CP [8, 9]. EUS-CPB was performed in patients with es-
tablished CP (≥4 criteria) or suspected CP (<4 criteria but with
clinical suspicion of CP). A linear echoendoscope (GF-UC140P-
AL5, GF-UC30P; Olympus America) was used to identify the ce-
liac trunk and celiac ganglia. A fine (22-gauge) aspiration needle
(EchoTip; Cook Medical, Winston-Salem, North Carolina, or Ex-
pect; Boston Scientific, Natick, Massachusetts) or a 20-gauge ce-
liac plexus needle (ECHO-20-CPN; Cook Medical) was passed
through the working channel of the curvilinear echoendoscope.
The needle was directed through the gastric wall into the celiac
region. If celiac ganglia were identified, they were targeted. If ce-
liac ganglia were not observed, the area lateral or anterior to the
celiac trunk was injected with either a unilateral or bilateral ap-
proach, according to the endosonographer’s preference. Sterile
saline was used to “test” proper needle positioning. Suction was
applied to the syringe to confirm the absence of blood return. A
few milliliters of saline was injected to clear the needle of con-
taminant from the gastric wall. Once the needle was properly po-
sitioned, the EUS technician injected 20mL of 0.75% bupivacaine
followed by 40 to 80mg of triamcinolone (EUS-CPB). The amount
of triamcinolone varied according to the endosonographer’s dis-
cretion. The echoendoscope was then withdrawn, and the pa-
tient was observed in the recovery area for approximately 1
hour. After the procedure, all patients received 1L of normal sal-
ine intravenously and 1 dose of an intravenous antibiotic (ampi-
cillin/sulbactam or ciprofloxacin), followed by a 3– to 5-day
course of an oral antibiotic (amoxicillin / clavulanate or ciproflox-
acin).
Definitions
Major adverse events were defined as aspiration, perforation, in-
fection, bleeding or pain that required hospitalization, paralysis
or other permanent injury, and death [10]. Minor adverse events
were defined as a transient increase in pain, diarrhea, orthostasis,
or sedation-associated hypotension or oxygen desaturation. Pa-
tients were defined as having established CP if 4 or more EUS fea-
tures of CP were documented, and suspected pancreatitis if fewer
than 4 features were present, but with a clinical suspicion of CP.
Statistical methods
Descriptive statistics were presented as mean and standard de-
viation. Nonparametric data were presented as median and
range. Generalized estimating equations were used to examine
the association between the effectiveness of first EUS-CPB and
the effectiveness of subsequent EUS-CPB, the number of EUS fea-
tures of CP, and the patient’s age at first EUS-CPB. Backward elim-
ination was used to determine the final model.
Results
!
Study population
A total of 1108 patients underwent at least one EUS-CPB proce-
dure during the 17-year study period between 1996 and 2012.
Of these, 248 patients underwent two or more EUS-CPB proce-
dures, and these made up our study cohort. Effectiveness data
were available for 233 patients, but safety data were available
for the entire cohort. The mean (SD) age was 43.8 (12.3) years,
and 171 patients (69%) were female. The CP was most commonly
idiopathic (●" Table1).
EUS-CPB was performed in 248 patients with established or sus-
pected CP. The median (range) number of EUS criteria for CP was
3 (0–8), and 72 patients had 4 or more EUS criteria for CP. The
main pancreatic duct was dilated in 27 patients and a pancreatic
stone was seen in 4, of whom 18 underwent endoscopic retro-
grade cholangiopancreatography (ERCP) drainage without reso-
lution of abdominal pain. Themean (SD) number of EUS-CPB pro-
cedures per patient was 3.1 (1.6). The most frequently used med-
ication for EUS-CPB was bupivacaine with triamcinolone (90%).
Effectiveness of EUS-CPB
After the first EUS-CPB, 76% of the patients reported pain relief,
and the median (range) duration of pain relief was 10 (1–54)
weeks. Data for the duration of efficacy after each subsequent
EUS-CPB are presented in●" Table2. Lack of pain relief after the
first EUS-CPB was associated with failure to achieve pain relief
after subsequent EUS-CPB (OR 0.17, 95%CI 0.06–0.54) (●" Fig.1).
The number of EUS criteria for CP was not associated with pain
Table 1 Patient characteristics.
CP (N=248)
Age, mean (SD) 43.8 (12.3)
Gender, No. female (%) 171 (69)
Race, No. (%)
Caucasian 224 (90)
African American 22 (9)
Other 2 (1)
Etiology of CP, No. (%)
Idiopathic 107 (43)
Alcohol 41 (17)
Other 14 (6)
Not documented 86 (34)
Medications used, No. (%)
Bupivacaine + triamcinolone 689 (90)
Bupivacaine 60 (8)
Other 18 (2)
Number of EUS-CPB procedures
Mean (SD) 3.1 (1.6)
Median (range) 2.5 (2–10)
CP, chronic pancreatitis; EUS-CPB, endoscopic ultrasound–guided celiac plexus block.
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relief after the first block (P=0.10) (●" Fig.2). Older age at first
block (P=0.026) and achieving pain relief after the first block (P
=0.0024) were associated with pain relief after subsequent
blocks. For every 10-year increase in age, patients were 1.60
times more likely to obtain pain relief (95%CI 1.06, 2.43). Patients
who experienced pain relief after the first EUS-CPB were 6.7
times more likely to experience relief after subsequent blocks
(95%CI 2.25–19.72).
Adverse events
There were 3 minor adverse events that occurred during the pro-
cedures (hypotension in 1 patient and hypoxemia to 70% in 2 pa-
tients); these resolved without clinically significant consequen-
ces. Transient diarrhea developed in 4 patients, and transient
light-headedness occurred in 2 patients following the procedure.
No major adverse events occurred during the study period.
Discussion
!
Little is known about the number of percutaneous or endoscopic
CPB procedures that can be safely performed in a single patient.
To our knowledge, this is the first study of the number of EUS-
CPB procedures performed in a single patient and the associated
procedure-related adverse events. Our study contributes several
new findings to the EUS literature.
First, our study provides the first report of the long-term safety of
repeated EUS-CPB procedures in a single patient. We observed
that patients who had CP underwent up to 10 EUS-CPB proce-
dures without serious adverse events. The majority of patients,
however, underwent 4 or fewer EUS-CPB procedures. Thus, our
findings may not be generalizable to patients who have had
more than 4 EUS-CPB procedures. Our study is also not adequate-
ly powered to detect rare adverse events (<1%), which would re-
quire a much larger sample size. Still, given the paucity of large
EUS-CPB trials, retrospective studies such as ours provide some
evidence about the safety of repeated EUS-CPB.
Overall, EUS-CPB is a relatively safe procedure, and adverse
events are infrequent and usually minor. Known and reported
adverse events include transient diarrhea (4%–15%), transient
orthostasis (1%), and temporary increase in pain (9%) More ser-
ious adverse events have been reported, and these include para-
plegia, paresthesia, spinal cord infarction, sexual dysfunction,
chemical pericarditis, abscess, gastroparesis, gastric necrosis, he-
morrhage, perforation, and rarely death [11–22]. These rare ad-
verse events have occurred after both percutaneous and EUS-
guided blocks and neurolysis. Although unproven, the proximity
of the celiac plexus to the tip of the echoendoscope should theo-
retically result in fewer adverse events.
Secondly, we found that response to the initial EUS-CPB for CP ap-
peared to be predictive of response to subsequent blocks. Alter-
natively, failure to achieve pain relief after the first EUS-CPB was
associatedwith lack of pain relief after the second block (OR 0.17,
95%CI 0.06–0.54). Although EUS-CPB is generally considered
safe, the likelihood of the success of a subsequent procedure
should influence the decision to repeat EUS-CPB for CP. This im-
portant finding has not been previously reported.
Prior studies of EUS-CPB for CP have reported a response in 50%
to 80% of patients [3,5,23,24]. A meta-analysis of EUS-guided
blocks and neurolysis reported response rates of 59% in CP and
80% in pancreatic cancer [25]. These studies, however, reported
the response after a single session. In addition, the definition of
“pain relief” varied from study to study. Our response rate of
76% for the initial EUS-CPB for CP is at the higher end of the
spectrum but comparable with the rates in the existing litera-
ture.
The major limitation of our study is its retrospective design.
Treatment response was based on a patient’s subjective report
of pain reduction or elimination. Further standardization of this
definition was not possible because of our retrospective design.
However, the willingness of a patient to return for another block
and/or the referring physician’s opinion that another block
would beworthwhile supports the notion that the prior response
is clinically meaningful. Other factors influencing the number of
EUS-CPB procedures that a patient might undergo were not
tracked, such as surgery for pain control and subsequent CPB pro-
cedures at an outside institution. We also did not report on the
Table 2 Effectiveness of serial EUS-CPB for chronic pancreatitis over time.
Block
No.
Total No.
with effective-
ness data
No.(%)
effective
Median (range)
duration of effective-
ness, wk
1 233 177 (76.0) 10 (1–54)
2 107 84 (78.5) 12 (2–53)
3 57 49 (86.0) 15 (2–79)
4 35 35 (100.0) 12 (2–60)
5 22 22 (100.0) 17.5 (1–38)
6 12 11 (91.7) 12 (2–56)
7 6 6 (100.0) 23 (7–30)
8 5 5 (100.0) 12 (1–46)
9 3 3 (100.0) 20 (12–27)
10 1 1 (100.0) 17 (17–17)
EUS-CPB, endoscopic ultrasound–guided celiac plexus block.
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effect of direct ganglia injection because this was not done during
the first 12 years of the study period, after which direct ganglia
injection was done almost exclusively during the last 4 years,
after the technique had been described. We did not compare
these two groups because many other changes in EUS-CPB devel-
oped during this time period that could not be entirely controlled
for in an analysis. A selection bias for responders likely existed in
our study. It is common in clinical practice for patients who re-
spond to therapy to be more likely to return for another proce-
dure. This may have contributed to our high response rate. With
respect to adverse events, it is possible that a major complication
might have occurred without our knowledge if the patient was
treated at an outside hospital. Given the nature of our tertiary re-
ferral center, however, this is unlikely because patients and refer-
ring physicians are instructed to contact the EUS physician
should an adverse event occur.
Conclusion
!
Repeated EUS-CPB in the same patient appears to be safe, with-
out major adverse events. Response to the first EUS-CPB for CP
appears to be predictive of response to subsequent blocks. A pro-
spective study is warranted to confirm our findings.
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